ROTH Capital Partners to Host Innovations in Oncology Corporate Access Day in New York on November 17, 2016

NEWPORT BEACH, Calif.–(BUSINESS WIRE)– ROTH Capital Partners (ROTH), www.roth.com,
a full service investment bank focused on serving emerging growth
companies and their investors, today announced that it will host its
Innovations in Oncology Corporate Access Day on Thursday, November 17,
2016 at the Lotte New York Palace in New York City.

ROTH’s Innovations in Oncology Corporate Access Day will give
investors the opportunity to interact with senior management of a select
group of Oncology and Targeted Therapeutics companies. There will also
be a keynote luncheon with Oncology expert Sotirios G. Stergiopoulos,
MD, MBEE, Vice President and Head of Global Medical Affairs Oncology at
SHIRE.

The event will allow for extensive interaction and 1-on-1 meetings with
management teams, providing in-depth insights into each company.

ROTH biotechnology research analysts Joe Pantginis, Ph.D., Michael
Higgins and Mark Breidenbach, Ph.D., will be available to discuss their
perspectives regarding the companies attending and their views regarding
the current biotechnology market trends.

“Oncology continues to represent a significant unmet medical need,
despite many recent revolutionary advances such as the immune checkpoint
inhibitors. As the industry pushes well beyond the old mainstays of
chemotherapy and radiation into targeted and personalized therapies,
major insights continue to be learned about combination approaches,”
says Joe Pantginis, Ph.D, Senior Biotechnology Research Analyst at
ROTH. “These companies we are hosting represent, in our belief, a set of
companies with cutting edge technologies, as well as attractive market
caps for investors who look to take part in oncology investment.
Innovations in Oncology are attracting broad interest in the investment
community, physicians, and drug companies, and we expect the trend to
continue as more positive data read out.”

“Given the rapid developments and changing dynamics in this sector, our
objective of this corporate access day is to provide investors with
direct interactions with management teams of a select group of leading
Oncology companies,” commented John W. Chambers, Vice Chairman and Head
of Healthcare Investment Banking at ROTH. “These companies will be
available for 1-on-1 meetings with investors to present their
technology, clinical development strategies, clinical achievements to
date and upcoming milestones and catalysts. The event is intended to
enable investors to gain direct insight into the key value drivers for
this group of innovative companies.”

ROTH has built a leading Healthcare Investment Banking Group over the
last several years and has raised approximately $12 billion in over 340
Healthcare transactions since 2010. *Past Performance is not indicative
of future returns. (Source: ROTH Capital Partners | 11/03/2016)

The event is for institutional clients of ROTH and is by invitation
only. For more information, please contact your ROTH sales
representative at (949) 720-5700 or e-mail: conference@roth.com

Thursday | November 17, 2016
8:00 am – 9:00 am |
Registration and Morning Coffee
8:45 am – 9:00 am | Introduction by
ROTH Senior Research Analysts
9:00 am – 4:45 pm | 1-on-1 / Small
Group Meetings
12:00 pm – 1:00 pm | Luncheon with Oncology expert
Sotirios G. Stergiopoulos, MD, MBEE

Venue | Hotel
Lotte New York Palace
455 Madison Avenue
New
York City, NY 10022 | Tel: (212) 888-7000

Participating Companies
The following participating
companies are confirmed as of the date of this release (as of 11/02/2016)

Aduro BioTech, Inc. (ADRO)
Argos Therapeutics, Inc. (ARGS)
Celldex
Therapeutics, Inc. (CLDX)
Fate Therapeutics, Inc. (FATE)
Fortress
Biotech, Inc. (FBIO)
Lion Biotechnologies, Inc. (LBIO)
MacroGenics,
Inc. (MGNX)
Nektar Therapeutics (NKTR)
Pieris Pharmaceuticals,
Inc. (PIRS)
Sorrento Therapeutics, Inc. (SRNE )
StemlineTherapeutics,
Inc. (STML)
Syndax Pharmaceuticals, Inc. (SNDX)
TG
Therapeutics, Inc (TGTX)
VBL Therapeutics (VBLT)
Viralytics
Ltd (VLA)

Event sponsors include Equisolve, Ellenoff Grossman & Schole LLP and
Business Wire.

About ROTH Capital Partners, LLC:

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment
bank focused on serving emerging growth companies and their investors.
As a full-service investment bank, ROTH provides capital raising, M&A
advisory, analytical research, trading, market-making services and
corporate access. Headquartered in Newport Beach, CA, ROTH is
privately-held and employee owned, and maintains offices throughout the
U.S. For more information on ROTH, please visit www.roth.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161104005117/en/